ArticleClinical and experimental nephrology2025
Long-term prognosis of pure membranous lupus nephritis: a comparison with proliferative lupus nephritis in Japan.
Article in Clinical and experimental nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rapid versus conventional glucocorticoid tapering in pure membranous LN: a multicentre retrospective study.Rheumatology advances in practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMembranous lupus nephritis (MLN), a distinct subtype of lupus nephritis (LN), is generally associated with more favorable outcomes than proliferative LN (PLN). However, clinical data regarding pure MLN are limited. We investigated the prognosis of patients with pure MLN in Japan.
methodsWe performed a sub-analysis of a previously reported nationwide retrospective cohort study of patients with LN in Japan. This study included patients who underwent renal biopsy between 2007 and 2012. Patients with pure MLN (Class V, n = 90) were compared to those with PLN (Class III/IV ± V, n = 362) over a median follow-up period of 5 years. The primary outcome was defined as a 50% increase in serum creatinine (S-Cr) levels.
resultsThe renal and patient outcomes of the pure MLN and PLN groups were as follows: A ≥ 50% increase in S-Cr occurred in 12.2 vs. 16.3% of patients. Doubling of S-Cr or progression to end-stage kidney disease (ESKD) occurred in 4.4 vs. 8.6%, ESKD alone in 2.2 vs. 3.0%, and all-cause mortality in 7.9 vs. 5.5%. After adjusting for age, sex, baseline renal function, proteinuria, and the use of mycophenolate mofetil or intravenous cyclophosphamide, no significant differences in renal outcomes were observed between groups (hazard ratio 0.564; 95% confidence interval 0.272-1.170; P = 0.124).
conclusionIn this nationwide Japanese cohort, no statistically significant differences in renal outcomes were observed between pure MLN and PLN. Further research is needed to explore strategies to improve outcomes in pure MLN.
Indexed as
Identifiers
40465063What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.